Avient Corporation
AVNTAvient Corporation's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: the price moved +13.0% in a year while annual EPS moved −51.6% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a confirmed uptrend (5 weeks in) while the P/E sits at the 50th percentile of its own 4-year range. Underneath, the last four quarters read improving, and 230% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Avient Corporation trades at $38.2, in a confirmed uptrend and 5 weeks into that stage. That is +8.7% against its own 200-day average. It sits at 66% of a 52-week range of $29 to $43. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (7 weeks and counting).
Today the stock is in a confirmed uptrend — week 5 of stage 2. At $38.2 it trades +8.7% versus its 200-day average and sits at 66% of its 52-week range ($29–$43).
Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +5% while the S&P 500 moved +263% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (7 weeks and counting; last ahead the week of 2026-06-18) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Avient Corporation trades at 22.2× P/E, mid-range by its own standards (50th percentile). Its long-run median P/E is 22.2×, measured across 4.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 22.2× is mid-range by its own standards (50th percentile), against a long-run median of 22.2× measured over 4.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −51.6% against a +13.0% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 3y, of the −0.9%/yr price move, ~−35.2%/yr came from earnings growth and ~+34.3 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Improving Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Avient Corporation reads as improving on its fundamental arc. Improving — EPS growth bottomed 8 quarters ago at −83.0% and has held its recovery at +60.7%, ROCE holding at 6.0%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: a sustained climb off the trough is the setup this page is built to catch — the question moves to what you pay for it.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +0.6% | −1.4% | — | — |
| Profit | −52.9% | +0.0% | — | — |
| EPS | −51.6% | −51.1% | — | — |
| Stock price | +13.0% | −0.9% | −4.4% | +0.7% |
4-Factor Sector Score
52.2/100 — rank 12 of 29 in Specialty Chemicals · 64% evidence confidence
Avient Corporation scores 52.2 out of 100 against the 29 companies it is compared with in Specialty Chemicals, ranking 12. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 21.8 + 9.1 + 10.9 + 10.4 = 52.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Avient Corporation reported $0.8 B of revenue in the Mar 26 quarter, +2.4% year on year. That is the 2nd straight quarter of year-on-year growth. Over 4 years it has compounded at −0.5% a year. The last full year, FY25, came in at $3.3 B. The last four reported quarters add to $3.3 B.
FY25 revenue came in at $3.3 B (+0.6% on the year), capping 4 years at −0.5% compound. The latest quarter (Mar 26) printed $0.8 B, +2.4% year on year — the 2nd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +1.2% growth against the decade's −0.5% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +1.2% over the last 4 quarters against +2.7%/yr over the last 8 — stabilising; TTM profit +60.0% vs +20.6%/yr — accelerating.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Avient Corporation's operating margin is 11.8% in the Mar 26 quarter, +11.8 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 6.1% to 10.2%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 11.8%, +11.8 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 6.1%–10.2%.
Why the margin moved: operating margin went +11.8 pp year on year while gross margin went +0.5 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Avient Corporation earned $0.1 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $0.1 B. The 4-year compound rate is −14.5%. That is 7.1% of the quarter's revenue. The same quarter a year earlier lost $0.02 B. 1 of the last 12 reported quarters were loss-making.
Mar 26 profit was $0.1 B, null year on year. On the full year, FY25 printed $0.1 B (−52.9%), and the 4-year compound rate is −14.5%.
Pace comparison, last four quarters: profit −6.1% vs revenue +1.2%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 230% of Avient Corporation's reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $0.3 B of operating cash against $0.1 B of profit. After $0.1 B of capital spending, $0.2 B was left as free cash.
FY25: operating cash of $0.3 B against reported profit of $0.1 B, leaving free cash of $0.2 B after $0.1 B of capital spending. Across the last 3 fiscal years the conversion rate is 230% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Avient Corporation does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Avient Corporation earns a ROE of 3% in FY25. Return on invested capital clears the cost of that capital by −1.2 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 2.5% net margin on 0.54× asset turns.
FY25 ROE is 3%.
🚨 Why the return is what it is — the wiring (FY25): 2.5% net margin × 0.54× asset turns × 2.52× balance-sheet leverage ≈ 3.4% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 7.4% − 8.6% = a −1.2 pp spread. The 8.6% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
Avient Corporation paid $1.09 per share over the last four reported quarters, up 1.9% on a year ago. The most recent declaration was $0.28 for Mar 26. Against the current price of $38.2 that is a trailing yield of 2.86%, measured on dividends already paid rather than on a forecast.
Avient Corporation paid $1.09 per share across the last four reported quarters, most recently $0.28 for Mar 26. That is up 1.9% against the same quarter a year earlier. Against the current price of $38.2 the trailing twelve months work out to 2.86% — trailing dividends measured against today's price, not a forward estimate.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Avient Corporation carries total debt of $1.9 B against shareholder equity of $2.4 B as of Mar 26, a debt-to-equity of 0.79. On the annual view that ratio went from 1.07 in FY21 to 0.80 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of $1.9 B against shareholder equity of $2.4 B — a debt-to-equity of 0.79. On the annual view, debt-to-equity went from 1.07 (FY21) to 0.80 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
4.7% of Avient Corporation's tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 4.0 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 4.7% of the float is sold short, and at typical trading volumes it would take about 4.0 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Avient Corporation: the Z-score reads 1.87. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits in the grey band between the two. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 1.87 sits in the grey band — neither clearly safe nor clearly distressed.
The safety line in one sentence: the Z-score reads 1.87.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1NewMarket CorporationNEU | 61.9/100Thin evidence · provisional58% evidence | BREAKING OUT | 16.9/35 Revenue — · PAT — · OPM change -1.4 pp 45% evidence | 16.1/25 ROCE 5.5% · OPM 21.4% 76% evidence | 11.4/20 P/E 17× · PEG — 15% evidence | 17.5/20 RS sector 5.4% · RS bench 8.6% · 1Y 20.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 16.9 + 16.1 + 11.4 + 17.5 = 61.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2Sociedad Química y Minera de Chile S.A.SQM | 61.7/100Mixed-positive evidence81% evidence | ASLEEP | 28.8/35 Revenue 18.3% · PAT 48.4% · OPM change 17.4 pp 83% evidence | 15.8/25 ROCE 6.3% · OPM 41% 76% evidence | 15.1/20 P/E 28.4× · PEG 0.81 65% evidence | 2.0/20 RS sector -9.7% · RS bench -8.3% · 1Y 62.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 28.8 + 15.8 + 15.1 + 2 = 61.7 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -9.7% and the one-year return is 62.4%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 3WD-40 CompanyWDFC | 61.3/100Thin evidence · provisional58% evidence | TURNING | 21.3/35 Revenue — · PAT — · OPM change 0.4 pp 45% evidence | 17.4/25 ROCE 10.8% · OPM 16.3% 76% evidence | 10.2/20 P/E 30.4× · PEG — 15% evidence | 12.4/20 RS sector -3.7% · RS bench -1.4% · 1Y 7.5%5 of 12 weeks ahead 100% evidence |
| Exact sum: 21.3 + 17.4 + 10.2 + 12.4 = 61.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4Sensient Technologies CorporationSXT | 60.7/100Thin evidence · provisional58% evidence | FADING | 20.4/35 Revenue — · PAT — · OPM change 1.7 pp 45% evidence | 12.8/25 ROCE 3.8% · OPM 15.3% 76% evidence | 9.8/20 P/E 33.2× · PEG — 15% evidence | 17.7/20 RS sector 7.9% · RS bench 10.5% · 1Y 9%8 of 12 weeks ahead 100% evidence |
| Exact sum: 20.4 + 12.8 + 9.8 + 17.7 = 60.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Quaker Chemical CorporationKWR | 57.5/100Thin evidence · provisional58% evidence | BREAKING OUT | 21.5/35 Revenue — · PAT — · OPM change 0.8 pp 45% evidence | 8.3/25 ROCE 1.7% · OPM 7% 76% evidence | 10.5/20 P/E 28.3× · PEG — 15% evidence | 17.2/20 RS sector 6% · RS bench 8.7% · 1Y 36.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 21.5 + 8.3 + 10.5 + 17.2 = 57.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6Axalta Coating Systems Ltd.AXTA | 56.2/100Thin evidence · provisional58% evidence | BREAKING OUT | 15.3/35 Revenue — · PAT — · OPM change -2.3 pp 45% evidence | 11.7/25 ROCE 2.8% · OPM 11.6% 76% evidence | 10.8/20 P/E 21.1× · PEG — 15% evidence | 18.4/20 RS sector 6.4% · RS bench 9.2% · 1Y 32.5%7 of 12 weeks ahead 100% evidence |
| Exact sum: 15.3 + 11.7 + 10.8 + 18.4 = 56.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7Ashland Inc.ASH | 54.2/100Thin evidence · provisional58% evidence | BREAKING OUT | 18.8/35 Revenue — · PAT — · OPM change -2.5 pp 45% evidence | 7.0/25 ROCE 1% · OPM 8.1% 76% evidence | 8.9/20 P/E 57.8× · PEG — 15% evidence | 19.5/20 RS sector 10.3% · RS bench 12.9% · 1Y 39%9 of 12 weeks ahead 100% evidence |
| Exact sum: 18.8 + 7 + 8.9 + 19.5 = 54.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8The Sherwin-Williams CompanySHW | 53.8/100Thin evidence · provisional58% evidence | TURNING | 18.7/35 Revenue — · PAT — · OPM change -0.1 pp 45% evidence | 15.5/25 ROCE 7.1% · OPM 14.2% 76% evidence | 10.0/20 P/E 31.7× · PEG — 15% evidence | 9.6/20 RS sector -6.6% · RS bench -4% · 1Y 2.7%1 of 12 weeks ahead 100% evidence |
| Exact sum: 18.7 + 15.5 + 10 + 9.6 = 53.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9H.B. Fuller CompanyFUL | 53.0/100Mixed-positive evidence85% evidence | BASING | 22.1/35 Revenue -0.6% · PAT 80.6% · OPM change 1.2 pp 95% evidence | 10.9/25 ROCE 2.6% · OPM 12.3% 76% evidence | 16.1/20 P/E 19× · PEG 0.5 65% evidence | 3.9/20 RS sector -14.3% · RS bench -12.2% · 1Y 4.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 22.1 + 10.9 + 16.1 + 3.9 = 53 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10International Flavors & Fragrances Inc.IFF | 52.4/100Mixed-positive evidence64% evidence | ASLEEP | 21.5/35 Revenue -5.6% · PAT — · OPM change 41.8 pp 62% evidence | 7.2/25 ROCE 1.2% · OPM 10% 76% evidence | 10.6/20 P/E 22.2× · PEG — 15% evidence | 13.1/20 RS sector 0% · RS bench 2.2% · 1Y 27.3%1 of 12 weeks ahead 100% evidence |
| Exact sum: 21.5 + 7.2 + 10.6 + 13.1 = 52.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Eastman Chemical CompanyEMN | 52.4/100Thin evidence · provisional58% evidence | ASLEEP | 18.6/35 Revenue — · PAT — · OPM change -4.6 pp 45% evidence | 13.3/25 ROCE 4.8% · OPM 8.6% 76% evidence | 11.2/20 P/E 17.4× · PEG — 15% evidence | 9.3/20 RS sector -5.5% · RS bench -3.5% · 1Y 19.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.6 + 13.3 + 11.2 + 9.3 = 52.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Avient Corporationthis pageAVNT | 52.2/100Mixed-positive evidence64% evidence | ASLEEP | 21.8/35 Revenue 1.3% · PAT 56.9% · OPM change 11.2 pp 62% evidence | 9.1/25 ROCE 1.9% · OPM 11.3% 76% evidence | 10.9/20 P/E 21.1× · PEG — 15% evidence | 10.4/20 RS sector -4.6% · RS bench -2.6% · 1Y 16.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 21.8 + 9.1 + 10.9 + 10.4 = 52.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Balchem CorporationBCPC | 52.2/100Thin evidence · provisional58% evidence | TURNING | 18.6/35 Revenue — · PAT — · OPM change 0.1 pp 45% evidence | 14.6/25 ROCE 3.8% · OPM 20.5% 76% evidence | 9.9/20 P/E 33.2× · PEG — 15% evidence | 9.1/20 RS sector -5.8% · RS bench -3.6% · 1Y 9.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.6 + 14.6 + 9.9 + 9.1 = 52.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14RPM International Inc.RPM | 50.2/100Thin evidence · provisional58% evidence | TURNING | 18.3/35 Revenue — · PAT — · OPM change 0.8 pp 45% evidence | 12.7/25 ROCE 4.8% · OPM 5% 76% evidence | 11.0/20 P/E 20.5× · PEG — 15% evidence | 8.2/20 RS sector -8.3% · RS bench -5.8% · 1Y -3.8%1 of 12 weeks ahead 100% evidence |
| Exact sum: 18.3 + 12.7 + 11 + 8.2 = 50.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15PPG Industries, Inc.PPG | 50.2/100Thin evidence · provisional58% evidence | TURNING | 16.8/35 Revenue — · PAT — · OPM change -0.2 pp 45% evidence | 12.8/25 ROCE 3.6% · OPM 13.8% 76% evidence | 11.3/20 P/E 17.4× · PEG — 15% evidence | 9.3/20 RS sector -5.7% · RS bench -3.5% · 1Y 10.1%3 of 12 weeks ahead 100% evidence |
| Exact sum: 16.8 + 12.8 + 11.3 + 9.3 = 50.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16Element Solutions IncESI | 49.8/100Thin evidence · provisional58% evidence | ASLEEP | 17.7/35 Revenue — · PAT — · OPM change 0.3 pp 45% evidence | 10.6/25 ROCE 2.3% · OPM 13.3% 76% evidence | 8.8/20 P/E 64.5× · PEG — 15% evidence | 12.7/20 RS sector 6.6% · RS bench 8.2% · 1Y 62.7%7 of 12 weeks ahead 100% evidence |
| Exact sum: 17.7 + 10.6 + 8.8 + 12.7 = 49.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Linde plcLIN | 47.5/100Thin evidence · provisional58% evidence | ASLEEP | 18.8/35 Revenue — · PAT — · OPM change 0.9 pp 45% evidence | 14.3/25 ROCE 3.6% · OPM 27.8% 76% evidence | 9.7/20 P/E 33.5× · PEG — 15% evidence | 4.7/20 RS sector -10.3% · RS bench -8.3% · 1Y 2.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.8 + 14.3 + 9.7 + 4.7 = 47.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18Ecolab Inc.ECL | 46.7/100Thin evidence · provisional58% evidence | TURNING | 17.0/35 Revenue — · PAT — · OPM change 0.3 pp 45% evidence | 12.9/25 ROCE 3.5% · OPM 15.3% 76% evidence | 9.5/20 P/E 37.4× · PEG — 15% evidence | 7.3/20 RS sector -9% · RS bench -6.6% · 1Y 3.8%1 of 12 weeks ahead 100% evidence |
| Exact sum: 17 + 12.9 + 9.5 + 7.3 = 46.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Cabot CorporationCBT | 46.3/100Mixed-negative evidence81% evidence | ASLEEP | 8.9/35 Revenue -8.5% · PAT -31.2% · OPM change -3 pp 83% evidence | 13.3/25 ROCE 4.5% · OPM 14.3% 76% evidence | 16.5/20 P/E 14.2× · PEG 0.18 65% evidence | 7.6/20 RS sector -5.2% · RS bench -3.1% · 1Y 5%8 of 12 weeks ahead 100% evidence |
| Exact sum: 8.9 + 13.3 + 16.5 + 7.6 = 46.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 20Air Products and Chemicals, Inc.APD | 43.7/100Thin evidence · provisional58% evidence | BASING | 17.0/35 Revenue — · PAT — · OPM change 103.5 pp 45% evidence | 9.5/25 ROCE -5.8% · OPM 23.7% 76% evidence | 10.1/20 P/E 30.7× · PEG — 15% evidence | 7.1/20 RS sector -7% · RS bench -4.9% · 1Y 2.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17 + 9.5 + 10.1 + 7.1 = 43.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21Calumet, Inc.CLMT | 41.5/100Mixed-negative evidence64% evidence | BREAKING OUT | 9.4/35 Revenue -0.1% · PAT — · OPM change -11.7 pp 62% evidence | 3.0/25 ROCE -9.1% · OPM -16.6% 76% evidence | 10.3/20 P/E 30.3× · PEG — 15% evidence | 18.8/20 RS sector 40.5% · RS bench 42% · 1Y 189.2%9 of 12 weeks ahead 100% evidence |
| Exact sum: 9.4 + 3 + 10.3 + 18.8 = 41.5 · Decision use: Price leads the evidence: RS versus the benchmark is 42%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 22Perimeter Solutions, Inc.PRM | 40.4/100Thin evidence · provisional58% evidence | FADING | 10.0/35 Revenue — · PAT — · OPM change -50 pp 45% evidence | 7.5/25 ROCE -7.6% · OPM 58% 76% evidence | 9.0/20 P/E 53.3× · PEG — 15% evidence | 13.9/20 RS sector 7.8% · RS bench 10.3% · 1Y 84.7%10 of 12 weeks ahead 100% evidence |
| Exact sum: 10 + 7.5 + 9 + 13.9 = 40.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23DuPont de Nemours, Inc.DD | 38.9/100Mixed-negative evidence81% evidence | BASING | 22.2/35 Revenue 4% · PAT 40.7% · OPM change 5.2 pp 83% evidence | 7.5/25 ROCE 0.7% · OPM 11.1% 76% evidence | 4.3/20 P/E 45.4× · PEG 4.12 65% evidence | 4.9/20 RS sector -21.8% · RS bench -19.3% · 1Y -32.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 7.5 + 4.3 + 4.9 = 38.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Albemarle CorporationALB | 38.3/100Thin evidence · provisional53% evidence | ASLEEP | 20.0/35 Revenue — · PAT — · OPM change 14.5 pp 32% evidence | 9.2/25 ROCE 1.6% · OPM 16.3% 76% evidence | 9.1/20 P/E 47.9× · PEG — 15% evidence | 0.0/20 RS sector -22.9% · RS bench -21.8% · 1Y 60.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 20 + 9.2 + 9.1 + 0 = 38.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25Hawkins, Inc.HWKN | 37.8/100Thin evidence · provisional58% evidence | ASLEEP | 14.8/35 Revenue — · PAT — · OPM change -1.2 pp 45% evidence | 12.7/25 ROCE 4.4% · OPM 8.8% 76% evidence | 9.4/20 P/E 41.9× · PEG — 15% evidence | 0.9/20 RS sector -22.8% · RS bench -20.8% · 1Y -24.6%1 of 12 weeks ahead 100% evidence |
| Exact sum: 14.8 + 12.7 + 9.4 + 0.9 = 37.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26LyondellBasell Industries N.V.LYB | 33.4/100Adverse evidence71% evidence | ASLEEP | 13.1/35 Revenue -9.4% · PAT -164.8% · OPM change 1.8 pp 83% evidence | 6.5/25 ROCE 0.9% · OPM 3.3% 76% evidence | 8.6/20 P/E 76.1× · PEG — 15% evidence | 5.2/20 RS sector -5.6% · RS bench -4.2% · 1Y 24.6%2 of 12 weeks ahead 100% evidence |
| Exact sum: 13.1 + 6.5 + 8.6 + 5.2 = 33.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27The Chemours CompanyCC | 28.8/100Adverse evidence64% evidence | ASLEEP | 12.7/35 Revenue 0.6% · PAT -3836.4% · OPM change -2 pp 62% evidence | 4.4/25 ROCE 0.5% · OPM 1.9% 76% evidence | 8.5/20 P/E 225.5× · PEG — 15% evidence | 3.2/20 RS sector -7.7% · RS bench -6.6% · 1Y 47.1%5 of 12 weeks ahead 100% evidence |
| Exact sum: 12.7 + 4.4 + 8.5 + 3.2 = 28.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Westlake CorporationWLK | 26.1/100Adverse evidence64% evidence | BASING | 9.8/35 Revenue -8.6% · PAT -473.1% · OPM change -5.4 pp 62% evidence | 4.7/25 ROCE -1% · OPM -6.5% 76% evidence | 9.6/20 P/E 33.6× · PEG — 15% evidence | 2.0/20 RS sector -17.5% · RS bench -16.2% · 1Y 2.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 9.8 + 4.7 + 9.6 + 2 = 26.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Solstice Advanced Materials, Inc.SOLS | 46.2/100Thin evidence · provisional36% evidence | ASLEEP | 12.4/35 Revenue — · PAT — · OPM change -4.5 pp 39% evidence | 15.1/25 ROCE 9.6% · OPM 16.5% 76% evidence | 8.7/20 P/E 67.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —1 of 12 weeks ahead 0% evidence |
| Exact sum: 12.4 + 15.1 + 8.7 + 10 = 46.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Avient Corporation's stock price today?
Avient Corporation trades at $38.2, +13.0% over the past year. The company is valued at $4.0 B. The stock sits at 66% of its 52-week range of $29–$43, +8.7% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 5 weeks in. — as of 5 August 2026.
What were Avient Corporation's latest quarterly results?
Avient Corporation reported revenue of $0.8 B and net profit of $0.1 B for the Mar 26 quarter. Earnings per share were $0.61. The operating margin was 11.8%, 11.8 pp higher than a year earlier. — as of 5 August 2026.
What is Avient Corporation's revenue?
Avient Corporation reported revenue of $0.8 B in the Mar 26 quarter, +2.4% year on year. For the full FY25 fiscal year, revenue was $3.3 B (+0.6%). Over the last 4 years revenue compounded at −0.5% a year. — as of 5 August 2026.
What is Avient Corporation's profit?
Avient Corporation earned $0.1 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $0.1 B. The operating margin ran 11.8% in the latest quarter. — as of 5 August 2026.
What is Avient Corporation's market cap?
Avient Corporation's market capitalisation is $4.0 B at a stock price of $38.2. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
What is Avient Corporation's P/E ratio?
Avient Corporation trades at a P/E of 22.2×, at the 50th percentile of its own 4-year range, against a long-run median of 22.2×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.
Does Avient Corporation pay a dividend?
Yes — Avient Corporation declared $0.28 per share for Mar 26, and $1.09 per share across the last four reported quarters. The latest quarter is up 1.9% on the same quarter a year earlier. — as of 5 August 2026.
What is Avient Corporation's dividend per share?
Avient Corporation's most recently declared dividend is $0.28 per share for Mar 26, giving $1.09 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 5 August 2026.
What is Avient Corporation's dividend yield?
Avient Corporation's trailing dividend yield is 2.86%: $1.09 declared per share across the last four reported quarters, against a share price of $38.2. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 5 August 2026.
Is Avient Corporation overvalued?
On its own history, Avient Corporation looks mid-range against its own history: its P/E of 22.2× sits at the 50th percentile of its 4-year range (long-run median 22.2×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 5 August 2026.
How is Avient Corporation performing?
Avient Corporation is in a confirmed uptrend, 5 weeks in. Against the S&P 500 it has been behind on a trailing-13-week view for 7 weeks. This describes what the data did, not a rating. — as of 5 August 2026.
What stage is Avient Corporation in?
Improving — EPS growth bottomed 8 quarters ago at −83.0% and has held its recovery at +60.7%, ROCE holding at 6.0%. The read comes from the last 12 quarters of growth (revenue growth +1.2% latest, profit growth +60.0% latest, eps growth +60.7% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.
Is Avient Corporation in an uptrend?
Yes — the price is in a confirmed uptrend (week 5 of stage 2), trading +8.7% versus its 200-day average and at 66% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is Avient Corporation beating the market?
Not lately — on a trailing-13-week view Avient Corporation is currently behind the S&P 500 (7 weeks and counting; last ahead the week of 2026-06-18), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +5% against the S&P 500's +263% — behind the index over the full window. — as of 5 August 2026.
Will Avient Corporation's stock price go up?
This page publishes no price forecast for Avient Corporation. What it measures instead: the stock price is $38.2, the price is in a confirmed uptrend 5 weeks in. Its P/E of 22.2× sits at the 50th percentile of its own 4-year range. — as of 5 August 2026.
Is the market betting against Avient Corporation?
Somewhat — short interest is 4.7% of Avient Corporation's tradable float, about 4.0 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Does Avient Corporation have too much debt?
It is moderate — Avient Corporation's debt-to-equity is 0.80. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 5 August 2026.
What is Avient Corporation's capex?
Avient Corporation spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.1 B. — as of 5 August 2026.
What is Avient Corporation's cash flow?
Avient Corporation generated $0.3 B of operating cash flow in FY25 and $0.2 B of free cash flow after $0.1 B of capital spending. Reported profit that year was $0.1 B, so operating cash ran ahead of profit. — as of 5 August 2026.
Is Avient Corporation's profit real cash?
Yes — over the last 3 fiscal years, 230% of Avient Corporation's reported profit arrived as operating cash. In FY25, operating cash was $0.3 B against reported profit of $0.1 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.
How financially safe is Avient Corporation?
On the balance sheet, the Z-score reads 1.87 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is in the grey band — neither clearly safe nor clearly distressed. — as of 5 August 2026.
Where is Avient Corporation in its business cycle?
Avient Corporation's FY25 operating margin was 6.1%, against a 5-year band of 6.1%–10.2%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 11.8%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the Avient Corporation story?
The sharpest disagreement: the price moved +13.0% in a year while annual EPS moved −51.6% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is Avient Corporation a stock worth studying right now?
This is not investment advice. The machine read: Avient Corporation's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.